Loading...

Satraplatin in the treatment of hormone-refractory metastatic prostate cancer

Satraplatin is an orally bioavailable platinum chemotherapeutic agent under development for several cancer types, including hormone-refractory prostate cancer (HRPC). Satraplatin is being developed for the treatment of men with chemorefractory HRPC for several reasons: 1) relative ease of administra...

Full description

Saved in:
Bibliographic Details
Main Authors: Armstrong, Andrew J, George, Daniel J
Format: Artigo
Language:Inglês
Published: Dove Medical Press 2007
Subjects:
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2376074/
https://ncbi.nlm.nih.gov/pubmed/18473011
Tags: Add Tag
No Tags, Be the first to tag this record!